Switch theme
Sign up to access all valuation multiples
SpectraCure AB develops treatment planning and laser light dose management for cancer treatment. The Company has developed its software IDOSE, and medical laser devices for the treatment.
2003
12
LTM Revenue n/a
LTM EBITDA n/a
$6.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
SpectraCure has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, SpectraCure achieved revenue of n/a and an EBITDA of -$2.1M.
SpectraCure expects next 12-month revenue of XXX and NTM EBITDA of XXX
See SpectraCure valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | $0.3M | $1.0M | XXX | XXX | XXX |
| Gross Margin | Infinity% | Infinity% | XXX | XXX | XXX |
| EBITDA | -$1.8M | -$2.1M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$2.6M | -$2.1M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 13, 2025, SpectraCure's stock price is SEK 1 (or $0).
SpectraCure has current market cap of SEK 78.7M (or $8.1M), and EV of SEK 65.5M (or $6.8M).
See SpectraCure trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.8M | $8.1M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 13, 2025, SpectraCure has market cap of $8.1M and EV of $6.8M.
SpectraCure's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate SpectraCure's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for SpectraCure and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $6.8M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -3.3x | XXX | XXX | XXX |
| P/E | -3.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSpectraCure's NTM/LTM revenue growth is n/a
SpectraCure's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, SpectraCure's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate SpectraCure's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for SpectraCure and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | N/A | XXX | XXX | XXX | XXX |
| EBITDA Margin | N/A | XXX | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | N/A | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SpectraCure acquired XXX companies to date.
Last acquisition by SpectraCure was XXXXXXXX, XXXXX XXXXX XXXXXX . SpectraCure acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was SpectraCure founded? | SpectraCure was founded in 2003. |
| Where is SpectraCure headquartered? | SpectraCure is headquartered in Sweden. |
| How many employees does SpectraCure have? | As of today, SpectraCure has 12 employees. |
| Who is the CEO of SpectraCure? | SpectraCure's CEO is Dr. Masoud Khayyami, PhD. |
| Is SpectraCure publicy listed? | Yes, SpectraCure is a public company listed on STO. |
| What is the stock symbol of SpectraCure? | SpectraCure trades under SPEC ticker. |
| When did SpectraCure go public? | SpectraCure went public in 2015. |
| Who are competitors of SpectraCure? | Similar companies to SpectraCure include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of SpectraCure? | SpectraCure's current market cap is $8.1M |
| Is SpectraCure profitable? | Yes, SpectraCure is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
